
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Immunol. , 08 April 2024
Sec. Cytokines and Soluble Mediators in Immunity
Volume 15 - 2024 | https://doi.org/10.3389/fimmu.2024.1386412
This article is a correction to:
Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE
A Corrigendum on
Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE
by Wong C, Stoilova I, Gazeau F, Herbeuval J-P and Fourniols T (2024). Front. Immunol. 15:1355845. doi: 10.3389/fimmu.2024.1355845
In the published article, there was an error in the Funding statement. A funding information was not included in the article. The correct Funding statement appears below.
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. CW is a student from the FIRE PhD program funded by the Bettencourt Schueller foundation and the EURIP graduate program (ANR-17-EURE-0012). IS is a student from the MTCI PhD program, and this work was supported by the Fondation pour la Recherche Médicale, grant number ECO202306017404.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: extracellular vesicles, secretome, immune regulation, mesenchymal stromal cell, priming, systemic lupus erythematosus
Citation: Wong C, Stoilova I, Gazeau F, Herbeuval J-P and Fourniols T (2024) Corrigendum: Mesenchymal stromal cell derived extracellular vesicles as a therapeutic tool: immune regulation, MSC priming, and applications to SLE. Front. Immunol. 15:1386412. doi: 10.3389/fimmu.2024.1386412
Received: 27 March 2024; Accepted: 27 March 2024;
Published: 08 April 2024.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2024 Wong, Stoilova, Gazeau, Herbeuval and Fourniols. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jean-Philippe Herbeuval, amVhbi1waGlsaXBwZS5oZXJiZXV2YWxAcGFyaXNkZXNjYXJ0ZXMuZnI=; Thibaut Fourniols, dGhpYmF1dC5mb3VybmlvbHNAZXZlcnpvbS5jb20=
†These authors have contributed equally to this work and share last authorship
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.